Physician profile
Ronald Lindquist
NPI 1073698031
$3,634.68
in general payments reported to CMS, 2019-2025
23 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $972 · 2022: $1,214 · 2023: $961 · 2024: $329 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,448.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,628.30 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $470.76 | 2021-2023 | Xifaxan |
| Celgene Corporation | $294.12 | 2022-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $186.74 | 2021-2023 | Gattex, Entyvio |
| Nestle Healthcare Nutrition INC. | $175.14 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $120.34 | 2024-2025 | Iqirvo |
| Ardelyx, INC. | $89.74 | 2023-2024 | Ibsrela |
| Genzyme Corporation | $81.25 | 2022-2023 | |
| Daiichi Sankyo INC. | $75.29 | 2022-2023 | Injectafer |
| Redhill Biopharma INC. | $75.08 | 2021 | |
| Pfizer INC. | $65.13 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $61.88 | 2022-2023 | Dupixent |
| Pharmacosmos Therapeutics INC. | $41.68 | 2022 | |
| Braintree Laboratories, INC. | $41.35 | 2021 | |
| Ironwood Pharmaceuticals, INC | $37.53 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $35.77 | 2022-2023 | Rebyota |
| Amag Pharmaceuticals, INC. | $34.53 | 2021 | |
| Amgen INC. | $31.42 | 2021 | |
| Madrigal Pharmaceuticals | $23.71 | 2025 | Rezdiffra |
| Lilly USA, LLC | $18.62 | 2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $16.65 | 2021 | |
| Gilead Sciences, INC. | $15.04 | 2021 | |
| Merck Sharp & Dohme LLC | $14.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Lindquist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.